Alpha 2.0
Login Register
» Authors » Dimitris Paraskevis

Dimitris Paraskevis

Explore the profile of Dimitris Paraskevis including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 485
Followers 0
Related Specialties
Infectious Diseases
Biology
Microbiology
Top 10 Co-Authors
Anne-Mieke Vandamme
Angelos Hatzakis
Annemarie M J Wensing
Elisabeth Puchhammer-Stockl
Ricardo Camacho
Mika Salminen
Claudia Kucherer
Maja Stanojevic
Birgitta Asjo
Jean-Claude Schmit
Published In
J Acquir Immune Defic Syndr
J Infect Dis
AIDS
Reprod Biol Endocrinol
Bioinformatics
Affiliations
Soon will be listed here.
Recent Articles
1.
HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics
Abecasis A, Wensing A, Paraskevis D, Vercauteren J, Theys K, van de Vijver D, et al.
Retrovirology . 2013 Jan; 10:7. PMID: 23317093
Background: Understanding HIV-1 subtype distribution and epidemiology can assist preventive measures and clinical decisions. Sequence variation may affect antiviral drug resistance development, disease progression, evolutionary rates and transmission routes. Results:...
2.
Early hCG addition to rFSH for ovarian stimulation in IVF provides better results and the cDNA copies of the hCG receptor may be an indicator of successful stimulation
Drakakis P, Loutradis D, Beloukas A, Sypsa V, Anastasiadou V, Kalofolias G, et al.
Reprod Biol Endocrinol . 2009 Oct; 7:110. PMID: 19825188
A simple, safe and cost-effective treatment protocol in ovarian stimulation is of great importance in IVF practice, especially in the case of previous unsuccessful attempts. hCG has been used as...
3.
The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes
van de Vijver D, Wensing A, Angarano G, Asjo B, Balotta C, Boeri E, et al.
J Acquir Immune Defic Syndr . 2006 Mar; 41(3):352-60. PMID: 16540937
Background: The genetic barrier, defined as the number of mutations required to overcome drug-selective pressure, is an important factor for the development of HIV drug resistance. Because of high variability...
4.
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management
Wensing A, van de Vijver D, Angarano G, Asjo B, Balotta C, Boeri E, et al.
J Infect Dis . 2005 Aug; 192(6):958-66. PMID: 16107947
Background: Infection with drug-resistant human immunodeficiency virus type 1 (HIV-1) can impair the response to combination therapy. Widespread transmission of drug-resistant variants has the disturbing potential of limiting future therapy...
5.
An automated genotyping system for analysis of HIV-1 and other microbial sequences
de Oliveira T, Deforche K, Cassol S, Salminen M, Paraskevis D, Seebregts C, et al.
Bioinformatics . 2005 Aug; 21(19):3797-800. PMID: 16076886
Motivation: Genetic analysis of HIV-1 is important not only for vaccine development, but also to guide treatment strategies, track the emergence of new viral variants and ensure that diagnostic assays...
6.
High prevalence of CRF02_AG and many minor resistance-related mutations at the protease gene among HIV-infected treatment-naive immigrants in Madrid
Vergne L, Paraskevis D, Vandamme A, Delaporte E, Peeters M
AIDS . 2003 Apr; 17(7):1105-7. PMID: 12700469
No abstract available.
7.
Reanalysis of the HIV-1 circulating recombinant form A/E (CRF01_AE): evidence of A/E/G recombination
Magiorkinis G, Paraskevis D, Magiorkinis E, Vandamme A, Hatzakis A
J Acquir Immune Defic Syndr . 2002 Jun; 30(1):124-9. PMID: 12048373
Circulating recombinant form (CRF) 01_AE caused an extensive HIV-1 epidemic in Thailand and Southeast Asia. Reanalysis of the recombination pattern of CRF01_AE suggested a more complicated pattern of mosaicism consisting...